A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.
Ian R WoodcockGeorge TachasNuket DesemPeter J HouwelingMichael KeanJaiman EmmanuelRachel A KennedyKate CarrollKaty de ValleJustine AdamsShireen R LamandéChantal ColesChrystal TiongMatthew BurtonDaniella VillanoPeter ButtonJean-Yves HogrelSarah Catling-SeyfferMonique M RyanMartin B DelatyckiEppie M YiuPublished in: PloS one (2024)
Clinical Trial Registration. Australian New Zealand Clinical Trials Registry Number: ACTRN12618000970246.